A Phase III Randomized Trial of Adjuvant Chemotherapy With or Without Bevacizumab for Patients With Completely Resected Stage IB (>/= 4 cm) - IIIA Non-Small Cell Lung Cancer (NSCLC)

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 19 Aug 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bevacizumab (Primary) ; Cisplatin; Docetaxel; Gemcitabine; Pemetrexed; Vinorelbine
Indications Carcinoma; Non-small cell lung cancer
Focus Registrational; Therapeutic Use

17 Nov 2023 Planned End Date changed from 16 Oct 2023 to 16 Oct 2024.
10 Sep 2019 Results of an Updated Chemotherapy Subset Analysis assessing outcomes by chemotherapy regimen with an additional 30 months of follow-up, presented at the 20th World Conference on Lung Cancer
09 Nov 2017 Results (n=1501) assessing the efficacy and tolerability of adjuvant antineoplastics [cisplatin + either carboplatin, docetaxel, gemcitabine, pemetrexed, or vinorelbine] with or without bevacizumab in patients with stage IB-IIIA non-small cell lung cancer, were published in the Lancet Oncology.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com